InvivoGen

InvivoGen is a biotechnology company that focuses on providing innovative, high-quality, and reliable reagents to life scientists globally. With a strong emphasis on cell culture engineering and innate immunity, the company operates from its three regional headquarters in Toulouse (France), San Diego (USA), and Hong Kong (China). Founded in 1977 in Toulouse, France, InvivoGen has expanded steadily, establishing offices in San Diego in 1997 and Hong Kong in 2014.

InvivoGen specializes in microbial fermentation, allowing it to produce a diverse range of bioactive molecules, including ultra-pure antibiotics, novel mycoplasma treatments, and an extensive collection of pattern recognition receptor agonists from various micro-organisms. The company's workforce of over 25% holders of PhDs in biology or chemistry collaborates seamlessly in R&D teams to create and validate novel plasmids, cell lines, vaccine adjuvants, and synthetic ligands for research in fields such as gene therapy, molecular immunology, and vaccination.

Furthermore, leveraging its in-depth understanding of innate immune receptor signaling pathways, InvivoGen has developed an expanding range of reporter cell lines, including cytokine reporter cells and knockout (KO) cell lines for high-priority innate immune targets. Researchers rely on InvivoGen for its commitment to quality, consistency, and reliability in providing essential tools and solutions for their work in various scientific endeavors.

As of now, specific details regarding the latest investment in InvivoGen and the involved investors are not available.